Lack of effect of Helicobacter pylori on symptom improvement with a prokinetic medication, cisapride, in patients with non-ulcer dyspepsia.

OBJECTIVE: This study was undertaken to determine whether H. pylori infection has an effect on the improvement of dyspeptic symptoms in response to a prokinetic agent, cisapride, in patients with non-ulcer dyspepsia (NUD). MATERIAL AND METHOD: 35 NUD patients (16 M, 19 F) who had no underlying medical condition and negative upper endoscopy were included in the present study. Each patient received a 2-wk treatment of cisapride (Prepulsid, 10 mg, tid ac). H. pylori infection was determined using a rapid urease test (CLO test). Gastric emptying (GE) scintigraphy and dyspeptic symptom scores were evaluated before and at the end of the treatment. GE was evaluated in 22 healthy volunteers as normal controls. RESULTS: Half time (T1/2) GE of NUD patients was 90.9 +/- 28 min which was significantly longer than controls (77.6 +/- 14 min; p < 0.05) and was shortened to 73.6 +/- 22 min (p < 0.0001) at the end of the treatment. Cisapride significantly improved total dyspeptic symptom scores [7 (2-18) to 3 (0-11), p < 0.0001]. The symptom score improvement was not affected by H. pylori infection [H. pylori positive: 6 (2-18) to 2.5 (0-9), p < 0.0001; H. pylori negative: 9 (4-16) to 3 (0-11), p < 0.0001] or GE status [delayed GE: 10 (5-16) to 3 (15), p < 0.05; non delayed GE: 6 (2-18) to 2 (0-11); p < 0.0001]. CONCLUSIONS: Cisapride improves dyspeptic symptoms regardless of H. pylori and GE status. These results suggest that gastric emptying and H. pylori infection are not essential to determine prior to prescribing a prokinetic agent, cisapride, in patients with NUD.

Relationship between vesicoureteral reflux and renal cortical scar development in Thai children: the significance of renal cortical scintigraphy and direct radionuclide cystography.

Relationship of vesicoureteral reflux (VUR), urinary tract infection (UTI) and subsequent renal scarring nowadays is still in question. This study aimed to determine 1) the incidence of cortical scarring in Thai children presenting with upper urinary tract infection, 2) the association between VUR with acute pyelonephritis and subsequent renal scarring, 3) the use of DMSA and direct radionuclide cystography (DRNC) scintigraphy in children with UTI. Sixty newly diagnosed UTI children underwent DRNC and Tc-99m DMSA renal cortical scintigraphy at the time of first UTI diagnosis and 6 months later. There were no significant differences of age, sex, type of antiobiotics and pathogens (E. coli vs non-E. coli) between those who did and did not develop scars (p>0.05). 58/98 of 1st DMSA abnormal kidneys (59.18%) developed scars. 60.20 per cent of 98 positive 1st DMSA had VUR while 80.33 per cent of 61 with VUR had positive 1st DMSA. 59.02 per cent of these 61 kidneys developed scars. Scar occurrence were 18.7 times in high grade VUR compared to low grades. In conclusion, there was a high incidence of acute pyelonephritis in the presence of VUR but acute pyelonephritis does not necessarily need VUR for its development. High grade reflux with upper UTI, is a strong indicator for renal scarring. Children presenting with UTI, irrespective of age, sex, or pathogen, should have both DMSA and DRNC scintigraphy performed to identify upper UTI and high risk patients who will develop subsequent renal scarring.